UCL and Moorfields Eye Hospital receive £5 million toward eye health research facility Oriel
An investment from the Sir Jules Thorn Charitable Trust will support a state-of-the-art building, opening in 2027
Toku obtains CE and UKCA marks for AI cardiovascular risk assessments through the eye
Toku’s AI technology, CLAiR, provides fast, accurate, non-invasive cardiovascular disease (CVD) risk assessments using standard retinal images
Extracellular vesicles could be the future of retinal diseases
How this treatment paradigm could change ocular cell therapy
Angiogenesis 2024: Highlighting 72-week results from the BALATON and COMINO Phase 3 studies of faricimab in retinal vein occlusion
Ramin Tadayoni, MD, PhD, highlights data from the BALATON and COMINO Phase 3 studies about faricimab
Voyager study provides data on real-world effectiveness of faricimab for nAMD and DME
Robyn Guymer, MBBS, PhD, reported the Voyager study’s preliminary data at the 2024 Angiogenesis, Exudation, and Degeneration conference
Angiogenesis 2024: Targeting Ang2 and VEGF – Biology, Pharmacokinetics and Latest Clinical Data in nAMD and DME
Dr Jennifer Lim reveals new data on Angiopoietin-2 inhibition and insights on clinical trial design
Angiogenesis 2024: The implication of longitudinal AI-based fluid quantification for at-home monitoring
Anat Loewenstein, MD, illuminates the outcomes of using an AI-based fluid quantification for remote retina monitoring and analysis
Angiogenesis 2024: Findings from the DAVIO 2 trial, assessing EYP-1901 vs aflibercept for wet AMD
Dr Carl Regillo provided an overview of topline results – and a deep dive into subgroup analyses – of DAVIO 2 trial data
Angiogenesis 2024: Expanded efficacy data from the GATHER 2 trial
Sydney M Crago, editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial, presented at the 2024 Angiogenesis Symposium
Angiogenesis 2024: Distinguishing aspects of early-onset AMD
EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants
Multimodal assessment of OCT adds perspective on GA and AMD progression
Researchers aimed to develop a translational map to understand how advanced imaging biomarkers manifest in typical diagnostic imaging
Kiora Pharmaceuticals and Théa Open Innovation announce partnership, will target IRDs
Kiora Pharmaceuticals and Théa Open Innovation will develop and commercialise KIO-301 for the treatment of inherited retinal diseases
Case report: diversifying cataract outcomes
Many options with one single Nd:YAG laser
AI ocular screenings facilitate early intervention for paediatric patients
Enhanced detection and diagnosis of common and severe diseases
How biosimilars expand treatment options for patients with retinal disease
An in-depth case study conversation
What do you do when there is no cataract?
Standalone, minimally-invasive glaucoma treatments
Plan your day: afternoon sessions at the Angiogenesis, Exudation, and Degeneration 2024 Conference
The afternoon sessions begin after lunch and continue well into the evening at the Angiogenesis, Exudation, and Degeneration 2024 meeting
Angiogenesis, Exudation and Degeneration Conference: A 1-day virtual symposium of all things retina
The one-day event will be held online Saturday, February 3, 2024, and is sponsored by the Bascom Palmer Eye Institute, University of Miami Health System
Iridex and Imperial College Healthcare NHS Trust announce collaborative MicroPulse TLT study
The partnership establishes a large-scale enrollment platform for research on MicroPulseTransscleral Laser Therapy (TLT)
Corneas harvested from patients who died of drowning are viable for transplantation
Postoperative outcomes of the tissues obtained from these donors were satisfactory
Intra-anterior chamber anti-VEGF injections feasible treatment for advanced paediatric vitreoretinal diseases
Investigators advised that further studies should be conducted to understand more precisely the benefits and risks
NEI shares outcomes from workshop on cerebral/cortical visual impairment
Clinicians, researchers and stakeholders discussed establishing CVI diagnostic criteria, boosting awareness of CVI and creating a participant data registry
Disease management and data integration: Zeiss Meditec looks ahead following Dutch Ophthalmic Research Center announcement
Euan Thomson, Head of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit at Carl Zeiss Meditec, discusses plans for the company's vitreoretinal surgery workflows following announcement of DORC acquisition
Morrow and Novacel Optical partner ahead of eProgressive smart glasses distribution
A strategic distribution partnership is expected to make Morrow’s eProgressive smart glasses available to consumers in the second quarter of 2024
Rayner announces acquisition of Swiss Ophthalmology Innovation and Sophi phaco technology
The UK-based Rayner announced the acquisition will enhance its portfolio in the cataract surgery space
AAO welcomes 128th president, Jane C. Edmond, MD, to 2024 term
Dr Edmond has also served as president of the American Association for Paediatric Ophthalmology and Strabismus and an oral examiner for the American Board of Ophthalmology
Annexon outlines ANX007 global pivotal programme for geographic atrophy, beginning mid-2024
The trial will use vision preservation as a primary outcome measure, according to Annexon
Technology company Gentex announces acquisition of ocular device developer eSight
eSight, a wearable assistive technology company, produces comprehensive equipment for patients with over 20 ocular disorders
UK ophthalmology students report impact of COVID-19 on clinical education
A reduction in clinical exposure has harmed student confidence, according to a questionnaire administered in the United Kingdom
European Commission grants EU marketing authorisation for aflibercept (Eylea) 8 mg
The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME
